Status:
UNKNOWN
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Lead Sponsor:
Zhongda Hospital
Conditions:
HCC
Eligibility:
All Genders
18+ years
Brief Summary
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combinati...
Detailed Description
This study is a multi-center, retrospective and observational real-world study to explore the efficacy, safety and treatment pattern of TACE combined with Atezolizumab + Bevacizumab in unresectable he...
Eligibility Criteria
Inclusion
- All patients were diagnosed with unresectable hepatocellular carcinoma according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition);
- Patients ≥ 18 years old, male or female;
- Child-Pugh Class A and B liver function;
- ECOG-PS score of 0 \~ 2 points;
- Received TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
Exclusion
- Other primary malignancies;
- Incomplete data, such as no baseline image that can be assessed according to RECIST 1.1 or mRECIST, and survival outcome.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06024252
Start Date
September 1 2023
End Date
June 1 2024
Last Update
September 6 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.